Rheumatology International

, 28:1187

4 years after withdrawal of rofecoxib: where do we stand today?



On the 24th of October 2006, the European Medicines Agency (EMEA) stated that “it cannot be excluded that non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) may be associated with a small increase in the absolute risk for thrombotic events”. Reviewing the most recent literature including meta-analyses of randomized clinical studies and pharmacoepidemiological studies show that this statement contrasts with the 2005 EMEA evaluation of cyclooxygenase-2 inhibitors, which contained a number of regulations including several contraindications for coxibs. Recent clinical data indicate that the entire substance group of NSAIDs may have cardiovascular side effects but to different degrees. Results of basic research support these observations showing that the increase for cardiovascular risk not only depends on the ratio of inhibition of thromboxan and prostacyclin but also on other mechanisms including blood pressure elevation and cyclooxygenase independent actions. In clinical practice, many patients require anti-inflammatory therapy with NSAIDs but are at high cardiovascular and gastrointestinal risk. The combination of nsNSAIDs with proton pump inhibitors shows comparable safety to coxibs in averting upper gastrointestinal events, but evidence is increasing coxibs have advantages regarding lower gastrointestinal side effects. Concomitant therapy with aspirin is another issue. There is a negative effect on gastrointestinal safety, as well as the influence of nsNSAIDs on the cardioprotective effect of aspirin. As the contraindications for coxibs announced by the EMEA may prevent some patients from receiving optimal treatment, a warning for the entire substance group, as issued by the American Food and Drug Administration, with no contraindictions, would certainly be more reasonable.


COX-2 Inhibitors NSAIDs Gastrointestinal risk Cardiovascular risk 


  1. 1.
    Singh G, Triadafilopoulos G (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 26(Suppl 56):18–24Google Scholar
  2. 2.
    Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 231:232–235PubMedGoogle Scholar
  3. 3.
    Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10 a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866–12872PubMedGoogle Scholar
  4. 4.
  5. 5.
  6. 6.
    Tramer MR, Moore RA, Reynolds DJM, McQuay HJ (2000) Quantitative estimation of rare adverse eventswhich follow a biological progression: a new model applied to chronic NSAID use. Pain 85:169–182PubMedCrossRefGoogle Scholar
  7. 7.
    Zimmermann KC, Sarbia M, Schror K, Weber AA (1998) Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 54:536–540PubMedGoogle Scholar
  8. 8.
    Wallace JL, McKnight W, Reuter BK, Vergnolle N (2000) NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119:706–714PubMedCrossRefGoogle Scholar
  9. 9.
    García Rodríguez LA, Hernández-Díaz S, de Abajo FJ (2001) Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52:563–571PubMedCrossRefGoogle Scholar
  10. 10.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM 343:1520–1528PubMedCrossRefGoogle Scholar
  11. 11.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284:1247–1255PubMedCrossRefGoogle Scholar
  12. 12.
    Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, on behalf of the TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET) reduction in ulcer complications: randomised controlled trial. Lancet 364(9435):675–684PubMedCrossRefGoogle Scholar
  13. 13.
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929–1933PubMedCrossRefGoogle Scholar
  14. 14.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS (2000) Reduced risk of upper gastrointestinal ulcer complications with celecoxib a novel COX-2 inhibitor. Am J Gastroenterol 95:1681–1960PubMedCrossRefGoogle Scholar
  15. 15.
    Edwards JE, McQuay HJ, Moore RA (2004) Efficacy and safety of valdecoxib for treatment of osteoarthrosis and rheumatoid arthritis: a systematic review of randomised controlled trials. Pain 111:286–296PubMedCrossRefGoogle Scholar
  16. 16.
    Goldstein JL, Eisen GM, Agrawal N, Stenson WF, Kent JD, Verburg KM (2004) Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther 20:527–538PubMedCrossRefGoogle Scholar
  17. 17.
    Eisen GM, Goldstein JL, Hanna DB, Rublee DA (2005) Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther 21:591PubMedCrossRefGoogle Scholar
  18. 18.
    Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329:948PubMedCrossRefGoogle Scholar
  19. 19.
    Moore RA, Derry S, Makinson GT, McQuay HJ (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from clinical trial reports. Arthritis Res Ther 7:R644–R665PubMedCrossRefGoogle Scholar
  20. 20.
    Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP (2007) Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomised comparison. Lancet 369:465–473PubMedCrossRefGoogle Scholar
  21. 21.
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS (2005) Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week randomized double-blind comparison with celecoxib and placebo. Clin Ther 27(1):64–77PubMedCrossRefGoogle Scholar
  22. 22.
    Chan FKL, Hung LCT, Suen BY, Wu JCY, Lee KC, Leung VKS, Hui AJ, To KF, Leung WK, Wong VWS, Chung SCS, Sung JJY (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. NEJM 347:2104–2110PubMedCrossRefGoogle Scholar
  23. 23.
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community—acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292:1955–1960PubMedCrossRefGoogle Scholar
  24. 24.
    Vakevainen S, Tillonen J, Salaspuro M, Nuutinen H, Jousimies-Somer H, Farkkila M (2000) Hypochlorhydria induced by a proton pump inhibitor leads to intragastric microbial production of acetaldehyde from ethanol. Aliment Pharmacol Ther 14:1511–1518PubMedCrossRefGoogle Scholar
  25. 25.
    Yang Y, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947–2954PubMedCrossRefGoogle Scholar
  26. 26.
    Sturkenboom MC, Burke TA, Tangelder MJ, Dieleman JP, Goldstein JL (2003) Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 18:1137–1147PubMedCrossRefGoogle Scholar
  27. 27.
    Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF (1996) Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern 156(14):1530–1536CrossRefGoogle Scholar
  28. 28.
    Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI (1992) Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J 327:749–754Google Scholar
  29. 29.
    Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I (2005) A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128:1172–1178PubMedCrossRefGoogle Scholar
  30. 30.
    Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazol, and placebo. Clin Gastroenterol Hepatol 3:133–141PubMedCrossRefGoogle Scholar
  31. 31.
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124:288–292PubMedCrossRefGoogle Scholar
  32. 32.
    Chan FKL, Wong VWS, Suen BY, Wu JCY, Ching JYL, Hung LCT, Hui AJ, Leung VKS, Lee VWY, Lai LH, Wong GLH, Chow DKL, To KF, Leung WK, Chiu PWY, Lee YT, Lau JYW, Chan HLY, Ng EKW, Sung JJY (2007) Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blindrandomised trial. Lancet 369:1611–1626Google Scholar
  33. 33.
    Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36–40PubMedGoogle Scholar
  34. 34.
    Bertagnolli MM, Craig JE, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley R, Hoffmann N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. NEJM 355(9):873–884PubMedCrossRefGoogle Scholar
  35. 35.
    Arber N, Craig JE, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. NEJM 355(9):885–895PubMedCrossRefGoogle Scholar
  36. 36.
    Lanas A, Bresalier R, Sandler R, Bolognese J, Quan H, Oxenius B, Horgan K, Riddell R, Morton D, Baron J (2005) Upper gastrointestinal events associated with rofecoxib in a colorectal adenoma chemoprevention trial. Gastroenterology 129:371CrossRefGoogle Scholar
  37. 37.
    Goldstein JL, Bello AE, Spalding W, Suh SG, Fort JG (2005) Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. J Rheumatol 32:111–117PubMedGoogle Scholar
  38. 38.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 119:255–266PubMedCrossRefGoogle Scholar
  39. 39.
    Patrono C (2006) The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol 47:S1–S6PubMedCrossRefGoogle Scholar
  40. 40.
    Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of artherothrombosis. NEJM 353:2373–2383PubMedCrossRefGoogle Scholar
  41. 41.
    Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, De-Marco S, Tournier B, Vyas SN, FitzGerald GA (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J 345:1809–1817CrossRefGoogle Scholar
  42. 42.
    Renda G, Tacconelli S, Capone ML, Sacchetta D, Santarelli F, Sciulli MG, Zimarino M, Grana M, D’Amelio E, Zurro M, Price DS, Patrono C, De Caterina R, Patrignani P (2006) Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 800(3):264–274CrossRefGoogle Scholar
  43. 43.
    Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD (2006) Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20:2468–2475PubMedCrossRefGoogle Scholar
  44. 44.
    Hermann M (2006) Cyclooxygenase-2 and nitric oxide. J Cardiovasc Pharmacol 47:S21–S25PubMedCrossRefGoogle Scholar
  45. 45.
    Michell JA, Warner TD (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steriodal anti-inflammatory drugs. Nature Rev 5:75–85CrossRefGoogle Scholar
  46. 46.
    Hinz B, Dormann H, Brune K (2006) More pronounced inhibition of cyclooxygenase2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and Rofecoxib. Arthritis Rheum 54:282–291PubMedCrossRefGoogle Scholar
  47. 47.
    McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci 96:272–277PubMedCrossRefGoogle Scholar
  48. 48.
    Hawkey CJ (1999) COX-2 inhibitors. Lancet 353:307–314PubMedCrossRefGoogle Scholar
  49. 49.
    Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959PubMedCrossRefGoogle Scholar
  50. 50.
    Curfman GD, Morrissey S, Drazen JM et al (2005) Expression of concern: bombardier “comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis” N Engl J 2000 343:1520–8. NEJM 353:2813–2814PubMedCrossRefGoogle Scholar
  51. 51.
    Weir MR, Spreling RS, Reicin A, Gertz BJ (2003) Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program. Am Heart J 146:591–604PubMedCrossRefGoogle Scholar
  52. 52.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedCrossRefGoogle Scholar
  53. 53.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. NEJM 352:1092–1102PubMedCrossRefGoogle Scholar
  54. 54.
    Nissen SE (2006) Adverse cardiovascular effects of rofecoxib. NEJM 355:203–204PubMedCrossRefGoogle Scholar
  55. 55.
    Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, Hubbard RC, Hsu PH, Saidman LJ, Mangano DT (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125:1481–1492PubMedCrossRefGoogle Scholar
  56. 56.
    Nussmeier NA, Whelton Hoeft AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. NEJM 352:1081–1091PubMedCrossRefGoogle Scholar
  57. 57.
    White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB (2002) Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 89:425–430PubMedCrossRefGoogle Scholar
  58. 58.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH (2004) On behalf of the TARGET Study Group comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 463:675–684CrossRefGoogle Scholar
  59. 59.
    Kearny PM, Baigent C, Godwin J, Emberson H, Halls JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steriodal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302–1305CrossRefGoogle Scholar
  60. 60.
    McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633–1644PubMedCrossRefGoogle Scholar
  61. 61.
    Martin BK (ADAPT Research Group). Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). PLoS Clin Trials 1: e33. doi:10.1371/journal.pctr.0010033 http://clinicaltrials.plosjournals.org/perlserv/?request=get-document&doi=10.1371%2Fjournal.pctr.0010033
  62. 62.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Hejde D, Erdmann E, Laine L (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme : a randomised comparison. Lancet 368:1771–1781PubMedCrossRefGoogle Scholar
  63. 63.
    Harris RC (2002) Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 89:10D–17DPubMedCrossRefGoogle Scholar
  64. 64.
    Maillard M, Burnier M (2006) Comperative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 5:83–94PubMedCrossRefGoogle Scholar
  65. 65.
    Krum H, Aw TJ, Liew D, Haas S (2006) Blood pressure effects of COX-2 inhibitors. J Cardiovasc Pharmacol 47:S43–S48PubMedCrossRefGoogle Scholar
  66. 66.
    Harris RC (2006) COX-2 and the kidney. J Cardiovasc Pharmacol 47:S37–S42PubMedCrossRefGoogle Scholar
  67. 67.
    Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J (2006) Effects of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028–1035PubMedCrossRefGoogle Scholar
  68. 68.
    Zhang J, Ding EL, Song Jl (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619–1632PubMedCrossRefGoogle Scholar
  69. 69.
    Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF, Morrow JD, Vita JA (2003) Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42:310–315PubMedCrossRefGoogle Scholar
  70. 70.
  71. 71.
    Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Graziano JM (2003) Inhibition of clinical benefits of aspirinon first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 108:1191–1195PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Anaesthesiology and Intensive Care MedicineWilhelminenspital, der Stadt WienViennaAustria
  2. 2.Department of Internal MedicineHospital of the ElisabethinenKlagenfurtAustria

Personalised recommendations